DIAGENS-B (02526) saw its shares rise more than 7% again. As of the time of writing, the stock was up 6.02%, trading at HKD 299.2 with a turnover of HKD 27.43 million. Public information indicates that DIAGENS focuses on fundamental technological innovation in the field of AI medical imaging. Its self-developed iMedImage® medical imaging base model supports 19 imaging modalities and can enhance over 90% of clinical imaging scenarios. Leveraging extensive pre-training data, iMedImage® enables rapid training of specialized diagnostic models for specific diseases, achieving significant industry breakthroughs in "fewer samples, lower computing power, and faster training." Currently, AI AutoVision has been classified as a Class III innovative medical device by the National Medical Products Administration (NMPA). DIAGENS disclosed in its prospectus that, following communication with the NMPA's Center for Medical Device Evaluation in December 2025, it was confirmed that the regulatory body has no objections to the registration approval of AI AutoVision. Only relevant procedural and administrative matters remain to be completed. If ultimately approved for market launch, it will become the first intelligent chromosome karyotyping辅助 diagnostic software to be approved for sale in China.